Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).
Valenti M, Ibba L, Cascio Ingurgio R, Malagoli P, Carugno A, Campoli M, Carrera CG, Gaiani FM, Strippoli D, Mola F, Marzano AV, Zerbinati N, Minuti A, Costanzo A, Narcisi A. Valenti M, et al. Among authors: cascio ingurgio r. Dermatol Ther (Heidelb). 2024 Nov;14(11):2987-2997. doi: 10.1007/s13555-024-01270-5. Epub 2024 Oct 13. Dermatol Ther (Heidelb). 2024. PMID: 39397217 Free PMC article.
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study.
Gargiulo L, Ibba L, Bianco M, Di Giulio S, Alfano A, Cascio Ingurgio R, Facheris P, Perugini C, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: cascio ingurgio r. J Dermatolog Treat. 2024 Dec;35(1):2375102. doi: 10.1080/09546634.2024.2375102. Epub 2024 Jul 4. J Dermatolog Treat. 2024. PMID: 38964753 Free article. No abstract available.
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Cascio Ingurgio R, Malagoli P, Amoruso F, Balato A, Bardazzi F, Brianti P, Brunasso G, Burlando M, Cagni AE, Caproni M, Carrera CG, Carugno A, Caudullo F, Cuccia A, Dapavo P, Di Brizzi EV, Dini V, Gaiani FM, Gisondi P, Guarneri C, Lasagni C, Licata G, Loconsole F, Marzano AV, Megna M, Mercuri SR, Musumeci ML, Orsini D, Ribero S, Ruffo Di Calabria V, Satolli F, Strippoli D, Travaglini M, Trovato E, Venturini M, Zichichi L, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: cascio ingurgio r. J Dermatolog Treat. 2024 Dec;35(1):2350760. doi: 10.1080/09546634.2024.2350760. Epub 2024 May 7. J Dermatolog Treat. 2024. PMID: 38714323 Free article.
Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study.
Gargiulo L, Ibba L, Piscazzi F, Alfano A, Cascio Ingurgio R, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: cascio ingurgio r. J Eur Acad Dermatol Venereol. 2024 Feb;38(2):e152-e154. doi: 10.1111/jdv.19507. Epub 2023 Sep 20. J Eur Acad Dermatol Venereol. 2024. PMID: 37714196 No abstract available.
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.
Orsini D, Gargiulo L, Ibba L, Cascio Ingurgio R, Valenti M, Perugini C, Pacifico A, Maramao FS, Frascione P, Costanzo A, Narcisi A. Orsini D, et al. Among authors: cascio ingurgio r. J Dermatolog Treat. 2023 Dec;34(1):2220849. doi: 10.1080/09546634.2023.2220849. J Dermatolog Treat. 2023. PMID: 37288760 Free article.